I am sure I speak for all of us when I say how relieved I was to hear about the successful evacuation of our officials from Sudan.
Bob Menendez Jr.
The Public Record
Robert Menendez Jr. is an American politician serving as the U.S. representative for New Jersey's 8th congressional district since January 3, 2023. A member of the Democratic Party, he succeeded his father, Robert Menendez Sr., who has had a long career in politics. Menendez Jr. focuses on issues such as healthcare, education, and economic development, reflecting the needs of his constituents in New Jersey. He has been vocal about political integrity and has made statements regarding the need for reform within the political system.
I will be reintroducing my bipartisan NFIP Re Act, and I appreciate the Chairman is going to be having a hearing on flood insurance, which is critically important.
FEMA has long struggled to keep premiums affordable, but it appears that the NFIP's new rating methodology, called Risk Rating 2.0, has only made flood insurance more out of reach for working and middle-class families.
That is why I introduced a discussion draft for today's hearing, Mr. Chairman that would modernize FHA's ability to finance multifamily housing construction around the country.
That is what my bipartisan HELPER Act is, and we look forward to working with the Committee on that.
Congress is responsible for passing comprehensive immigration and border solutions to mitigate some of the challenges your Department is facing.
I am so glad that DHS is focused on this critical issue, because here in this committee, as you might be aware, Republicans refuse to include any reference to domestic terrorism in their partisan committee oversight plan for this Congress…
Black taxpayers are at least three times as likely to be audited by the Internal Revenue Service.
High list prices hurt patients who must pay these prices. If list prices were lower, out-of-pocket payments based on list prices would be lower and more affordable.
Pharmacy benefit managers are key players, or should be, in alleviating patients' financial burden at the pharmacy counter.
This level of concentration gives these PBMs market power over data, drug coverage, and contracting--80 percent.
PBMs benefit significantly from high list prices and have no incentive to choose lower-priced drugs to drive down patient costs.





